Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

Valery T. Miller(Unknown), Sally A. Shumaker(Wake Forest University), D Feddersen, Elizabeth Barrett‐Connor(University of California San Diego), Craig M. Kessler(Georgetown University), Róbert Langer(Massachusetts Institute of Technology), Gail A. Greendale(University of California, Los Angeles), Carl J. Pauerstein, Robert Marcus(Stanford University), Mary C. Sheehan(Stanford University), David Foster(University of Manchester), Mark A. Espeland(Wake Forest University), Marcia L. Stefanick(Stanford University), Donna Kritz‐Silverstein(University of California San Diego), Katherine A. O’Hanlan, Claudine Legault, José F. Trabal, Vanessa M. Barnabei, Diane B. Stoy, George Howard(University of Alabama at Birmingham), Alice McKenzie, Allison Akana, Richard Bayalos, Denise L. Krutzfeldt, Mercedes Rodriguez-Sifuentes, Ann Smith-Roth, J. Kyle Anderson, C. Kirchner, Robert S. Schenken(The University of Texas at San Antonio Health Science Center), Kathy Lozano, Susan R. Miller, Ginny Levin, H. Bradley Wells, Trudy L. Bush, Helmut G. Schrott, Howard L. Judd(University of California, Los Angeles), Melissa Ruyle, Howard A. Zacur, John C. LaRosa(SUNY Downstate Health Sciences University), J Bénda, Robert Byington, Michael P. Stern(The University of Texas at San Antonio Health Science Center), Kathy Kawakami, Carmela Cavero, Susan R. Johnson, Peter D. Wood(Stanford University), W L Heinrichs, Margaret E. Griffin, Mary Lou Carrion-Petersen
JAMA
January 18, 1995
Cited by 605


Related Papers